Table 6.
Intestinal health markers in fecal samples of patients with prediabetes of the PLC and MO groups during the intervention.
| 0 Weeks | 6 Weeks | 12 Weeks | MIXED Model p # | Rate of Change 0 Weeks–12 Weeks a |
||
|---|---|---|---|---|---|---|
| Calprotectin (µg/mL) | PLC | 25; 73 ± 95 | - | 30; 58 ± 70 | 0.851 | 0.0; 0.5 ± 1.6 |
| MO | 32; 58 ± 69 | - | 32; 59 ± 63 | 0.1; 0.6 ± 1.6 | ||
| NS | ||||||
| sIgA (µg/mL) | PLC | 1448; 2017 ± 1856 | - | 1402; 2208 ± 2437 | 0.941 | −0.1; 1.5 ± 5.8 |
| MO | 1343; 1663 ± 1478 | - | 1245; 2187 ± 2154 | −0.2; 1.0 ± 3.5 | ||
| NS | ||||||
Median, Mean ± SD. MIXED linear model with the repeated factor “visit” and the fixed factors “treatment” and “Fat_Status” and the interaction “visit × treatment” and “Fat_Status × treatment”; p # corresponds to “visit × treatment”. a ANCOVA with the fixed factor “treatment”, “Fat_Status” as confounder and the basal value as covariate; NS, not significant. PLC: placebo; MO: Moringa oleifera Lam.